THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121 | -14.8% | 14,069 | +2.5% | 0.00% | 0.0% |
| Q2 2023 | $142 | -16.0% | 13,723 | -11.8% | 0.00% | 0.0% |
| Q1 2023 | $169 | -99.8% | 15,565 | +35.1% | 0.00% | 0.0% |
| Q1 2022 | $110,000 | -4.3% | 11,525 | +10.6% | 0.00% | 0.0% |
| Q4 2021 | $115,000 | -50.6% | 10,423 | +8.6% | 0.00% | -50.0% |
| Q1 2018 | $233,000 | -44.0% | 9,599 | -35.7% | 0.00% | -33.3% |
| Q4 2017 | $416,000 | +274.8% | 14,931 | +205.5% | 0.00% | +200.0% |
| Q2 2016 | $111,000 | +68.2% | 4,887 | +40.2% | 0.00% | – |
| Q1 2016 | $66,000 | +73.7% | 3,486 | +51.3% | 0.00% | – |
| Q4 2015 | $38,000 | +11.8% | 2,304 | -25.9% | 0.00% | – |
| Q3 2015 | $34,000 | +183.3% | 3,108 | +229.2% | 0.00% | – |
| Q2 2015 | $12,000 | -7.7% | 944 | +28.8% | 0.00% | – |
| Q1 2015 | $13,000 | +18.2% | 733 | +0.5% | 0.00% | – |
| Q4 2014 | $11,000 | -45.0% | 729 | -16.0% | 0.00% | – |
| Q3 2014 | $20,000 | -28.6% | 868 | 0.0% | 0.00% | – |
| Q2 2014 | $28,000 | – | 868 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |